Clinical Trial Update: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing Lutetium-177Lu-Edotreotide to best standard of care in well-differentiated aggressive grade-2/grade-3 gastroenteropancreatic ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Gastroenteropancreatic Neuroendocrine Tumors

Drugs mentioned

• Lutetium-177Lu-Edotreotide (177Lu-edotreotide)

Snippet

Sponsor: ITM Solucin GmbH | Conditions: Neuroendocrine Tumors | Phase 3 | Status: ACTIVE_NOT_RECRUITING